AstraZeneca-Oxford COVID-19 vaccine disruptions continue

March 16, 2021

The Danish Health Authority has paused its vaccination campaign with the COVID-19 vaccine from AstraZeneca, as a precautionary measure while a full investigation is ongoing into reports of blood clots in people who received the vaccine, including one case in Denmark where a person died, according to a news release from the European Medicines Authority (EMA).

The EMA also said some of its other member states also have paused inoculations with this vaccine.

“There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine. The position of EMA’s safety committee PRAC is that the vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing. PRAC is already reviewing all cases of thromboembolic events, and other conditions related to blood clots, reported post-vaccination with COVID-19 Vaccine AstraZeneca,” the EMA said in the release.

The EMA also said the number of thromboembolic events in vaccinated people is no higher than the number seen in the general population. As of 10 March 2021, 30 cases1 of thromboembolic events had been reported among close to 5 million people vaccinated with COVID-19 Vaccine AstraZeneca in the European Economic Area.

Visit the EMA for more news

Photo 111134338 © Kwanchaidt | Dreamstime.com
Photo 81363766 © Andrii Kucher | Dreamstime.com
Photo 125378010 © Komgrit Pradissagul | Dreamstime.com
Photo 36810879 © Tyler Olson | Dreamstime.com